Zydus Lifesciences’ Maharashtra unit clears US FDA inspection with no observations
Zydus Lifesciences' US formulation sales for the third quarter stood at $285 million, which is a growth of 29% on a year-on-year basis. Shares of Zydus Lifesciences Ltd ended at ₹901.60, down by ₹40.85, or 4.33%, on the BSE.

What's Your Reaction?






